Hemisphere Media Group Inc. (NASDAQ: HMTV )
Founded in 2013, Hemisphere Media Group is a leading U.S. Spanish-language media company serving the U.S. Hispanic and Latin American markets. The Hemisphere Media Group is the only public company with a focus on Hispanic people living in the US and it also serves many Latina American countries.
Pay-TV subscribers in Latin America, not including Brazil, grew by 44% from 2012 to 2016, and are projected to grow an additional 15 million
from 53 million in 2016 to 69 million by 2021 representing projected growth of over 28%, while the U.S. census bureau estimates that the Hispanic population in the United States will grow to 70 million by 2025. The network has over 50 million subscribers and the management estimate that user base will continue to grow.
Advertising revenues and retransmission/subscriber fees are the main sources of revenues and it is important to monitor these two variables, as they have an impact on the stock price.
Technically, HMTV is in a sideline channel and in November it hits a low at $11, a lever which played as support in the last three years.
Accelerize Inc. (OTCBB: ACLZ)
Accelerize Inc. a technology company that operates in the cloud business and offers software solutions for businesses interested in expanding their online advertising spend. Accelerize is primarily focused on Enterprise process
apps and in 2016 its Global SaaS software reached $106b revenues, with an increase of 21% over the 2015. In a nine-months period ended September 30 the revenues increased from $17.883.105 to $18.016.552 while the cost of every single voice (Cost of Revenues; Sales and Marketing Expenses; General and Administrative Expenses; and other expenses) increased about 30%.
The company has an history of losses and has a substantial amount of indebtedness, while the management estimates the Costs of Revenues will continue to increase in the next months. If the management will be able to secure the company’s line of credits and to lift the company’s cost structure is highly probable that the stock price will climb over 1$ again.
Accelerize’s stock is sitting on its all time low from more than 2 year and the prices are moving in a sideline channel range of 0,55-0,25.
Netlist Inc. (NASDAQ:NLST)
Founded in 2000 by Jayesh Bhakta, Chun Ki Hong, and Christopher Lopes, Netlist’s main business is memory subsystems designed for datacenter server, high performance computing and communications markets.
The company has introduced over the years many disruptive products and in 2015 signed an a strategic partnership with Samsung to produce a new class of NVDIMM-P (NV-P) memory solutions.
Netlist incurred over a nine-months period ending in September 30 a net loss of $10.3 million and the company has an accumulated deficit of $154.913 million. The management believes the Company’s existing cash balance,
together with cash provided by the Company’s operations, will be enough to t to meet the Company’s anticipated cash needs for at least the next 12 months, but if the funds will be inadequate the Company will have to significantly modify its business model and/or reduce or cease its operations.
The stock is near its all time low and usually a rebound may occurs from this level.
NII Holdings Inc. (NASDAQ:SIEB)
Founded in 1995, NII Holdings is a provider of wireless communication services that operates mainly in Brazil. The group, once listed in the Fortune 500, went through bankruptcy in 2014, and in the same year reached an agreement with its major stakeholders on terms on a Chapter 11 reorganization plan.
In 2017 revenues were impacted by pressure on competitive forces and the wind down of iDEN business: on a nine-months period ended in September 30, the revenues dropped from $736.6 million to $680.7 million.
The company is still sitting on an big debt and it still failing to generate enough operating cash flows and earnings to cover annual interest expenses and there are risks of a new bankruptcy.
The stock is at its all time low and at the moment there are no signs of rebound. For this reason we recommend to wait next quarter and see if NII’s financial situation starts to recover.
Repros Therapeutics Inc.
Founded in 1987 as Zonagen, Repros Therapeutics is a US-based pharmaceutical company focused on the development of oral small molecule drugs to address hormonal and reproductive system disorders.
Proellex, a drug designed to treat symptoms linked to uterine fibroids and endometriosis, is still in Phase II development and the Food and Drug Administration (FDA) has put the drug under partial clinical hold.
Enclomiphene, another drug in Repros’ pipeline, is it not likely to receive a positive response to its marketing application by the European Medicines Agency’s advisory group.
Repros Therapeutics has been recently acquired by Allergan, but the deal is under investigation by Monteverde & Associates PC.
The company’s stock is on its all time low and much will depend on the product’s pipeline approval and on the future plans of Allergan.